Shamburg News · 8-K filed Nov 12, 2026, 4:11 PM EST
BioCardia Reports Q3 2026 Net Loss of $1.8 Million; Cash Runway Into 2027
BCDA · BioCardia, Inc.
- Earnings
- Materiality: high
BioCardia reported a net loss of $1.8 million, or $0.12 per share, for the third quarter ended September 30, 2026, compared with a net loss of $1.5 million, or $0.24 per share, a year earlier. The company ended the quarter with cash and cash equivalents of $2.2 million, providing anticipated runway into 2027. The company also reiterated upcoming regulatory milestones for its CardiAMP and Helix programs, including a Japan PMDA submission expected in Q4 2026 or Q1 2027.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001437749-26-036574.
Written from the filing by Shamburg Markets. Figures are as reported by the company.